Last update Nov. 8, 2023

M01AE14

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Dexibuprofen is a pharmacologically active enantiomer of the racemic ibuprofen used to treat pain and inflammation. Pharmacokinetically and clinically it behaves like ibuprofen itself  (Yoon 2008, Sádaba 2006). Oral administration in three daily doses. 

On latest update no published data about breastfeeding were found.

Its high binding to plasma proteins makes it unlikely to be excreted in breast milk in significant quantities.

As it is an enantiomer of ibuprofen, with similar pharmacokinetic characteristics, it is considered to have similar compatibility with breastfeeding.

Alternatives

  • Ibuprofen ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

M01AE14 is Dexibuprofen in ATC Code/s.

Is written in other languages:

Tradenames

Main tradenames from several countries containing M01AE14 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 95 %
Molecular weight 206 daltons
Protein Binding 99 %
VD 0.14 l/Kg
pKa 4.85 -
Tmax 2.2 hours
1.8 - 4.7 hours

References

  1. AEMPS. Dexibuprofeno. Ficha técnica. 2023 Full text (in our servers)
  2. Muralidharan S. Pharmacokinetic-pharmacodynamic model of newly developed dexibuprofen sustained release formulations. ISRN Pharm. 2012 Abstract Full text (link to original source) Full text (in our servers)
  3. Yoon JS, Jeong DC, Oh JW, Lee KY, Lee HS, Koh YY, Kim JT, Kang JH, Lee JS. The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection. Br J Clin Pharmacol. 2008 Abstract
  4. Sádaba B, Campanero MA, Muñoz-Juarez MJ, Gil-Aldea I, García-Quetglas E, Esteras A, Azanza JR. A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers. Eur J Clin Pharmacol. 2006 Abstract
  5. Medicines.org.uk. Dexibuprofen. Drug Summary. 2005 Full text (in our servers)
  6. Eller N, Kollenz CJ, Schiel H, Kikuta C, Mascher H. Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. Int J Clin Pharmacol Ther. 1998 Abstract

Total visits

97

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM